The management of immunosuppression in patients with inflammatory bowel disease and cancer

Gut

Volumn 62, Issue 11, 2013, Pages 1523-1528

  Bernheim, Oren ^a   Colombel, Jean Frederic ^a   Ullman, Thomas A ^a   Laharie, David ^b   Beaugerie, Laurent ^c   Itzkowitz, Steven H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CASPASE 10; CASPASE 8; CORTICOSTEROID; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; IPILIMUMAB; MERCAPTOPURINE; MESALAZINE; RAPAMYCIN; RNA; TIOGUANINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; COLITIS; COLON CANCER; CROHN DISEASE; DRUG WITHDRAWAL; ENTERITIS; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MELANOMA SKIN CANCER; MORTALITY; NEPHROBLASTOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOTHERAPY; RHEUMATOID ARTHRITIS; RISK REDUCTION; SARCOMA CELL; SKIN CANCER; TESTIS CANCER; THYROID CANCER; UTERINE CERVIX CANCER;

CANCER; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; TNF; ULCERATIVE COLITIS;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; PURINES; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885618122     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305300     Document Type: Article

References (43)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
2. Panccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab plus azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology 2011;140:S134-S.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 2013;19:1306-21.
5. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742-7. (Pubitemid 23122039)
6. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-7.
7. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167-98. (Pubitemid 46871026)
8. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18:446-9. (Pubitemid 39077081)
9. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9.
10. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011;92:303-10.
11. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37: 411-19.
12. Reinisch W, Panes J, Lemann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-92.
13. Beaugerie L, Carrat F, Chevaux J-B, et al. 622 Risk of subsequent cancer under immunosuppressive therapy in patients with inflammatory bowel disease and prior cancer: data from the CESAME prospective observational cohort. Gastroenterology 2012;142:S-122.
14. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010;62:755-63.
15. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
16. Ledingham J, Deighton C. British Society for Rheumatology Standards G. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63. (Pubitemid 40277395)
17. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
18. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83.
19. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24.
20. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012;61:476-83.
21. Rajca SBA, Sokol H, Beaugerie L, et al. Impact of extra-intestinal cancer on inflammatory bowel disease outcome. 2012;61(Supp 2):A158.
22. Sogaard KK, Cronin-Fenton DP, Pedersen L, et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2008;14:519-25. (Pubitemid 351571832)
23. Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-22.
24. Sultan K, Korelitz BI, Present D, et al. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1855-8.
25. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24-36.
26. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:119-30.
27. Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994;331:883-4. (Pubitemid 24289728)
28. Csuka ME, Hanson GA. Resolution of a soft-tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Arch Intern Med 1996;156:1573-6. (Pubitemid 26244442)
29. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19. (Pubitemid 38167313)
30. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
31. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
32. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-9. (Pubitemid 350035310)
33. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008;19:1340-6. (Pubitemid 351911969)
34. Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25. (Pubitemid 351227865)
35. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-9.
36. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175: 926-34. (Pubitemid 46684703)
37. Lees CW, Ironside J, Wallace WA, et al. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 2008;359:320-1. (Pubitemid 352008468)
38. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9. (Pubitemid 46630658)
39. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte- associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
40. Axelrad JE, Fowler SA, Friedman S, et al. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol 2012;10:1021-7e1.
41. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002;360:1969-70. (Pubitemid 35472143)
42. Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009;100:200-5.
43. Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-11. (Pubitemid 38660234)